Navigation Links
Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
Date:5/19/2010

ter, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

    For further information please contact:

    Investor Relations

    Clea Rosenfeld (Rest of the World)
    +44-1256 894-160

    Eric Rojas (North America)
    +1-781-482-0999

    Media

    Jessica Mann (Rest of the World)
    +44-1256 894-280

    Jessica Cotrone (North America, HGT)
    +1-617-613-4640



'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
2. Shires Replenished Portfolio Drives Excellent Quarterly Performance
3. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
4. Shire Supports Rare Disease Day 2010
5. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
6. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
7. Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
8. New Shire Board Member
9. Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
10. New CapSure™ Cleanroom Wiper from Berkshire Corporation Captures and Retains 42 Times More Contaminant Particles
11. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... severe flooding that devastated a wide swath of Colorado ... bridges, roads and other infrastructure had been upgraded or ... of Colorado Denver. , "People need to understand the ... associate professor of structural engineering at the CU Denver ... the study. "There is an assumption that a bridge ...
(Date:10/27/2014)... Mass. and TORONTO ... Corporation ( www.generex.com ) (OTCQB: GNBT) today announced ... immunological response triggered by its novel proprietary cancer ... relapse in breast cancer patients. The AE37 cancer ... subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ). The ...
(Date:10/27/2014)... Called the NOAH Protocol, this investigative ... of pediatric brain cancer. The implications for groundbreaking ... years of research and development. Amber Larkin, the ... mom's determination can make a difference. , ... it’s only fitting that we’ve received FDA approval ...
(Date:10/27/2014)... -- Investor-Edge has initiated coverage on the ... ), Insmed Inc. (NASDAQ: INSM ), BioCryst ... (NASDAQ: DYAX ), and Oncothyreon Inc. (NASDAQ: ... accessed at: http://investor-edge.com/register . On Friday, ... up 0.69%, the Dow Jones Industrial Average advanced 0.76%, ...
Breaking Biology Technology:CU Denver study says upgrading infrastructure could reduce flood damage 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
... invention from Tel Aviv University a network of tiny ... foil even the most determined intruder. Scattered outdoors on ... of a bank, the dewdrops are a completely new and ... , Prof. Yoram Shapira and his Tel Aviv University Faculty ...
... (R) (lacosamide) C-V, a new antiepileptic drug (AED), ... week of June 2009. Vimpat was approved by ... the use as an add-on therapy for the treatment ... with epilepsy.(Photo: http://www.newscom.com/cgi-bin/prnh/20090526/NY22555 )Vimpat approval is ...
... old man with inoperable lung cancer is able to ... Surgeons told Donald Bickford, 71, that due to ... not an option for removing his lung tumor. To ... Wentworth-Douglass Hospital here, prescribed a type of non-invasive radiosurgery ...
Cached Biology Technology:Intruder alert: Tel Aviv University's 'Smart Dew' will find you! 2Vimpat(R) (lacosamide) C-V, a New Antiepileptic Drug (AED), To Be Available in U.S. Pharmacies 2Vimpat(R) (lacosamide) C-V, a New Antiepileptic Drug (AED), To Be Available in U.S. Pharmacies 3Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology 2Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology 3
(Date:10/29/2014)... but they also need protection from its harmful rays, just ... in plants that shields them from sun damage. Now, in ... Society , one team reports on the mechanics of how ... at Purdue University note that the harsh ultraviolet radiation plants ... DNA and, as a result, hinder plant growth. Biochemical ...
(Date:10/29/2014)... German . ... Schlögelhofer at the Max F. Perutz Laboratories (MFPL) of ... Vienna dived into the process of meiosis in specific ... inversion of the standard meiotic phases. The researchers describe ... Communications . , Meiosis is the two-step series of ...
(Date:10/29/2014)... October 29, 2014 – Ghrelin is a hormone released ... intake. Alcohol is commonly viewed as a psychoactive substance ... a highly caloric food. , This knowledge, combined ... hypothesis that ghrelin has the potential to stimulate alcohol ... this in humans and found that, as they had ...
Breaking Biology News(10 mins):Meiotic cell division 'the other way round' 2Ghrelin stimulates an appetite for drinking alcohol 2
... analysis indicates that birds don,t fly alone when migrating at ... journeys, flying in tandem even when they are 200 meters ... University of Illinois and the Illinois Natural History Survey, appears ... is the first to confirm with statistical data what many ...
... numbers of cycles of preimplantation genetic diagnosis or screening ... in 2004 (the most recent year for which data ... a growing number of genetically related conditions, but what ... condition are available for transfer and the parents request ...
... the journal Plant Physiology provides a comprehensive ... the rapidly growing Rosaceae scientific community. ... that comprises more than 3,000 species, including strawberry, apple, ... high-value nutritional foods and they are also the source ...
Cached Biology News:Birds migrate together at night in dispersed flocks, new study indicates 2Birds migrate together at night in dispersed flocks, new study indicates 3Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 2Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 3Review article provides tools for the Rosaceae genomics community 2